What This Apogee Insider Move Might Mean After a 247% Stock Run

Transaction summary

Transaction worth based connected SEC Form 4 weighted mean merchantability terms ($133.63); post-transaction worth based connected July 10, 2026 marketplace adjacent ($133.65).

Key questions

• What was the superior mechanics for the reported sale?
  The merchantability of 20,000 shares was conducted pursuant to a Rule 10b5-1 trading program adopted connected August 13, 2025, providing a structured exit strategy that avoids imaginable conflicts regarding non-public information.

• How did the charitable acquisition impact the insider's position?
  Henderson talented 75,046 shares to a donor-advised fund; portion this reduced the nonstop stock count, it represents a transportation for philanthropic purposes alternatively than a market-based liquidation of equity.

• What is the company's existent fiscal illustration and show context?
  Apogee Therapeutics, which reported a nett nonaccomplishment of $274.6 cardinal for the trailing 12 months, has seen its banal terms make a 247% instrumentality implicit the one-year play ending July 10, 2026.

• What remains of the insider's full equity exposure?
  Following these transactions, Henderson retains 921,000 communal shares successful nonstop ownership.

Company Overview

Company Snapshot

• Apogee Therapeutics is simply a clinical-stage biotechnology institution processing biologic monoclonal antibody therapies, with pb programs including APG777 for atopic dermatitis and APG808 for chronic obstructive pulmonary disease, targeting ample inflammatory and immunological illness markets.

• The institution generates worth done the improvement and imaginable commercialization of proprietary subcutaneous extended half-life monoclonal antibodies designed to supply improved diligent convenience and therapeutic efficacy compared to existing attraction modalities.

• Apogee's people markets see patients with atopic dermatitis, COPD, and different inflammatory and immunological disorders, with commercialized opportunities spanning dermatology and respiratory therapeutic areas.

Apogee Therapeutics is simply a clinical-stage biotechnology institution headquartered successful Waltham with a focused pipeline of biologic therapies addressing important unmet aesculapian needs successful inflammatory and immunological disorders. The company's competitory strategy centers connected the improvement of extended half-life monoclonal antibodies designed to heighten diligent outcomes and attraction adherence. With a marketplace capitalization of $8.2 cardinal and important caller equity appreciation, Apogee represents a high-growth biotech concern thesis babelike connected palmy objective improvement and regulatory support of its pb candidates.